Saleem Zafar, MD
Urology · Toledo, OHNPI 1003085226
Payments from drug & device makers
Across 356 payments — averaging $37.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$3K
- Medtronic$2K
- Astellas Pharma US Inc$1K
- Neotract Inc.$1K
- Sumitomo Pharma America, Inc.$930
- Johnson & Johnson$482
- plus $4K from 32 others
What the payments were for
- Travel & lodging$3,46726%
- Food & beverage$9,21470%
- Education$5354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 11 | $3,174 |
| Medtronic | 16 | $1,582 |
| Astellas Pharma US Inc | 84 | $1,431 |
| Neotract Inc. | 6 | $1,220 |
| Sumitomo Pharma America, Inc. | 47 | $930 |
| Johnson & Johnson | 23 | $482 |
| Histosonics, Inc. | 2 | $444 |
| Antares Pharma, Inc. | 21 | $433 |
| Myovant Sciences Inc. | 31 | $408 |
| Blue Earth Diagnostics | 14 | $364 |
| Procept Biorobotics Corporation | 6 | $298 |
| Ferring Pharmaceuticals Inc. | 2 | $295 |
| Dendreon Pharmaceuticals LLC | 7 | $293 |
| Boston Scientific | 8 | $200 |
| Pfizer | 11 | $193 |
| Teleflex LLC | 5 | $168 |
| AbbVie(2 entities) | 8 | $144 |
| Conmed Corporation | 2 | $135 |
| Olympus America Inc. | 6 | $134 |
| AstraZeneca | 3 | $99 |
| Urovant Sciences Inc | 7 | $93 |
| Urogen Pharma, Inc. | 4 | $82 |
| Tolmar Pharmaceuticals, Inc. | 6 | $82 |
| Immunitybio, Inc. | 3 | $80 |
| Progenics Pharmaceuticals, Inc. | 3 | $71 |
| Endo Pharmaceuticals Inc. | 3 | $59 |
| Tolmar, Inc. | 3 | $53 |
| Halozyme Inc | 2 | $47 |
| Calyxo, Inc. | 2 | $44 |
| Axonics, Inc. | 2 | $36 |
| Endo USA, Inc. | 1 | $28 |
| Ambu Inc. | 1 | $22 |
| Coloplast | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$3,006
- UroLift$1,069
- INTERSTIM$608
- ADSTILADRIN$295
- AQUABEAM SYSTEM$222
- PROVENGE$128
- XTANDI$117
- AIRSEAL$109
How this compares
$13,217 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 51 | $729,045 |
| OrgovyxRelugolix | 173 | $462,827 |
| MyrbetriqMirabegron | 531 | $345,134 |
| GemtesaVibegron | 92 | $58,782 |
| XyostedTestosterone Enanthate | 33 | $20,936 |
| Mirabegron ErMirabegron | 29 | $18,906 |
| Tamsulosin Hcl | 1,095 | $14,284 |
| Silodosin | 96 | $9,869 |
| Solifenacin Succinate | 118 | $5,472 |
| Estradiol | 74 | $4,920 |
| Tadalafil | 30 | $4,588 |
| Potassium Citrate ErPotassium Citrate | 46 | $3,726 |
| Oxybutynin Chloride ErOxybutynin Chloride | 126 | $3,342 |
| Finasteride | 229 | $3,055 |
| Trimethoprim | 39 | $2,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,431 | $1,074,179582 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $930 | $521,610265 claims |
| Antares Pharma, Inc.Xyosted | $433 | $20,93633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 485 urology providers in Ohio.
Other urology in Toledo
- Michael ReesToledo$216K
- Firas PetrosToledo$127K
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.